<abstract xmlns="http://www.w3.org/1999/xhtml">Background. Small molecules that inhibit V600 mutated BRAF protein, such as vemurafenib and dabrafenib, are effective in treatment of metastatic melanoma. Case report. We here describe the clinical course of a V600E BRAF mutated metastatic melanoma patient with systemic disease, who developed tumor progression on superficial soft-tissue metastases during treatment with dabrafenib. Bleomycin electrochemotherapy during dabrafenib treatment was administered to control the soft-tissue progressing metastases and ensured sustained local control without significant toxicity. Conclusions. The new combined approach maintained the patient quality of life and allowed for the prosecution of the target therapy, which proved to be still effective on systemic disease, up to 17 months</abstract>

Background. Small molecules that inhibit V600 mutated BRAF protein, such as vemurafenib and dabrafenib, are effective in treatment of metastatic melanoma. Case report. We here describe the clinical course of a V600E BRAF mutated metastatic melanoma patient with systemic disease, who developed tumor progression on superficial soft-tissue metastases during treatment with dabrafenib. Bleomycin electrochemotherapy during dabrafenib treatment was administered to control the soft-tissue progressing metastases and ensured sustained local control without significant toxicity. Conclusions. The new combined approach maintained the patient quality of life and allowed for the prosecution of the target therapy, which proved to be still effective on systemic disease, up to 17 months

Consolidation electrochemotherapy with bleomycin in metastatic melanoma during treatment with dabrafenib

Melanoma Oncology Unit, Veneto Region Oncology Research Institute (IOV-IRCCS), Padova, Italy

Melanoma and Sarcoma Unit, Veneto Region Oncology Research Institute (IOV-IRCCS), Padova, Italy

Radiology and Oncology

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Background. Small molecules that inhibit V600 mutated BRAF protein, such as vemurafenib and dabrafenib, are effective in treatment of metastatic melanoma. Case...

Consolidation electrochemotherapy with bleomycin in metastatic melanoma during treatment with dabrafenib

Data publikacji: 03 mar 2015

Zakres stron: 71 - 74

Otrzymano: 10 cze 2014

Przyjęty: 31 lip 2014

DOI: https://doi.org/10.2478/raon-2014-0035

© by Sara Valpione

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.